Skip to main content

Madryn Asset Management Issues Presentation Detailing Why SomaLogic Shareholders Should Vote “AGAINST” the Value-Destructive and Deeply Flawed Proposed Merger with Standard BioTools

Encourages SomaLogic Shareholders to Visit to View Presentation and Learn How to Vote “AGAINST the Proposed Merger

Madryn Plans to Send a GREEN Proxy Card to SomaLogic Shareholders, and Urges All Shareholders to Vote “AGAINST the Merger on Any Proxy Card

Publishes List of Key Questions that Shareholders Should Be Asking SomaLogic

Madryn Asset Management, LP (“Madryn Asset Management” and, collectively with its affiliates, “Madryn”), a holder of approximately 4.2% of the outstanding common stock of SomaLogic, Inc. (“SomaLogic” or the “Company”) (Nasdaq: SLGC), today issued a presentation detailing why shareholders should reject the Company’s proposed merger (the “Proposed Merger”) with Standard BioTools Inc. (“Standard”) (Nasdaq: LAB).

Shareholders should visit for Madryn’s presentation and other materials, as well as information on how to vote.

Madryn also published the following list of top 10 questions that it believes shareholders should direct to the SomaLogic Board of Directors (the “Board”) in light of the numerous value-destructive and deeply flawed aspects of the Proposed Merger and the process undertaken to reach the Proposed Merger agreement:

  1. Why agree to a transaction at a time when SomaLogic’s share price was at an all-time low?
  2. Why would SomaLogic shareholders agree to an enterprise value that is negative based on today’s trading levels?
  3. Why would shareholders accept a valuation that doesn’t represent the recent re-rate in SomaLogic’s value after the announcement of the acquisition of Olink Holding AB (publ) (“Olink”) (Nasdaq: OLK)?
  4. Why would SomaLogic shareholders, who hold common stock in a cash-rich company with a clean balance sheet, agree to a Proposed Merger where they will become deeply subordinated to $300 million worth of debt or debt-like securities?
  5. Why would SomaLogic shareholders, who have a customary governance structure for a public company with a clean balance sheet, accept lesser voting, consent and governance provisions than preferred equity holders in the combined company?
  6. Why discount the potential for a standalone SomaLogic to create shareholder value, especially given prior optimistic statements made by Board members and management?1
  7. Was the Board aware that every member of the SomaLogic Transaction Committee (the “Transaction Committee”) has extensive business connections to a conflicted investor on both sides of the transaction, Casdin Capital, LLC? Why weren’t those connections disclosed, and how did the Board get comfortable with these directors serving on the Transaction Committee?
  8. Why did initial discussions with Standard terminate in November 2022?
  9. Why did several members of the Board and the former SomaLogic CEO, Roy Smythe, resign or retire in March 2023 (just before discussions with Standard resumed in April 2023)?
  10. Why were the minority investment opportunities identified in the sales process seemingly not moved forward?2

Madryn Urges SomaLogic Shareholders to Vote “AGAINST” the Proposed Merger at the Company’s January 4, 2024 Special Meeting

Voting “AGAINST” the Proposed Merger Will Protect the Value of Shareholders’ Investment and Allow SomaLogic to Pursue Vastly Superior Alternatives

Visit for Madryn’s Presentation and Other Materials, as Well as Information on How to Vote


About Madryn Asset Management

Madryn Asset Management is a leading alternative asset management firm that invests in innovative healthcare companies specializing in unique and transformative products, technologies and services. The firm draws on its extensive and diverse experience spanning the investment management and healthcare industries and employs an independent research process based on original insights to target attractive economic opportunities that deliver strong risk-adjusted and absolute returns for its limited partners while creating long-term value in support of its portfolio companies.


Madryn Asset Management, Madryn Health Partners, LP, Madryn Health Partners (Cayman Master), LP, Madryn Health Advisors, LP, Madryn Health Advisors GP, LLC, Madryn Select Opportunities, LP, Madryn Select Advisors, LP, Madryn Select Advisors GP, LLC and Avinash Amin (collectively, the “Participants”) are participants in the solicitation of proxies from the stockholders of SomaLogic in connection with the special meeting of stockholders (the “Special Meeting”). The Participants have filed with the U.S. Securities and Exchange Commission (the “SEC”) their definitive proxy statement and accompanying GREEN Proxy Card in connection with the solicitation of proxies from SomaLogic’s stockholders for the Special Meeting. MADRYN STRONGLY ADVISES ALL STOCKHOLDERS OF SOMALOGIC TO READ THE DEFINITIVE PROXY STATEMENT, THE ACCOMPANYING GREEN PROXY CARD AND OTHER DOCUMENTS RELATED TO THE SOLICITATION OF PROXIES BY THE PARTICIPANTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ADDITIONAL INFORMATION RELATED TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS IN SOMALOGIC, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some or all SomaLogic stockholders and will be, along with other relevant documents, available at no charge on the SEC’s website at In addition, the Participants will provide copies of the definitive proxy statement without charge, when available, upon request. Requests for copies should be directed to Madryn Asset Management.


This material does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in any state to any person. In addition, the discussions and opinions in this press release are for general information only, and are not intended to provide investment advice. All statements contained in this release that are not clearly historical in nature or that necessarily depend on future events are “forward-looking statements,” which are not guarantees of future performance or results, and the words “anticipate,” “believe,” “expect,” “potential,” “could,” “opportunity,” “estimate,” and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained in this press release that are not historical facts are based on current expectations, speak only as of the date of this press release and involve risks that may cause the actual results to be materially different. Certain information included in this material is based on data obtained from sources considered to be reliable. No representation is made with respect to the accuracy or completeness of such data, and any analyses provided to assist the recipient of this presentation in evaluating the matters described herein may be based on subjective assessments and assumptions and may use one among alternative methodologies that produce different results. Accordingly, any analyses should also not be viewed as factual and also should not be relied upon as an accurate prediction of future results. All figures are unaudited estimates and subject to revision without notice. Madryn disclaims any obligation to update the information herein and reserves the right to change any of its opinions expressed herein at any time as it deems appropriate. Past performance is not indicative of future results.


1 SomaLogic Q4 2022, Q1 2023 and Q2 2023 earnings calls.

2 SLGC-LAB Merger Proxy.


Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.